The coronavirus pandemic has so far claimed 7,171 lives, with at least 182,603 coronavirus cases reported and 79,881 people recovered. Today, the NIH begins clinical trial of investigational vaccine for COVID-19. While the trial launched in record speed, public health officials have been stressing for weeks that a vaccine won’t be ready for 12 to 18 months in the best circumstances.

However, there is good news today that an existing anti-viral medication may be effective at treating the COVID-19. According to a new academic study presented by Thomas R. Broker, (Stanford PhD), James M. Todaro (Columbia MD), and Gregory J. Rigano, Esq., in consultation with Stanford University School of Medicine, UAB School of Medicine, and National Academy of Sciences researchers, shows that over the counter anti-malaria pills Chloroquine may be highly effective at treating coronavirus COVID-19.

In a research work published on Friday, recent guidelines from South Korea and China report that chloroquine is an effective antiviral therapeutic treatment against Coronavirus Disease 2019. “Use of chloroquine (tablets) is showing favorable outcomes in humans infected with Coronavirus including faster time to recovery and shorter hospital stay. US CDC research shows that chloroquine also has strong potential as a prophylactic (preventative) measure against coronavirus in the lab, while we wait for a vaccine to be developed. Chloroquine is an inexpensive, globally available drug that has been in widespread human use since 1945 against malaria, autoimmune and various other conditions,” the authors said.

About this entry